1. Lipidated PrRP31 metabolites are long acting dual GPR10 and NPFF2 receptor agonists with potent body weight lowering effect.
- Author
-
Alexopoulou, Flora, Bech, Esben Matzen, Pedersen, Søren Ljungberg, Thorbek, Ditte Dencker, Leurs, Ulrike, Rudkjær, Lise Christine Biehl, Fosgerau, Keld, Hansen, Henrik H., Vrang, Niels, Jelsing, Jacob, and Elster, Lisbeth
- Subjects
- *
BODY weight , *G protein coupled receptors , *METABOLITES , *WEIGHT loss , *NEUROPEPTIDE Y , *NEUROPEPTIDES , *BIOAVAILABILITY , *PEPTIDES - Abstract
Prolactin-releasing peptide (PrRP) is an endogenous neuropeptide involved in appetite regulation and energy homeostasis. PrRP binds with high affinity to G-protein coupled receptor 10 (GPR10) and with lesser activity towards the neuropeptide FF receptor type 2 (NPFF2R). The present study aimed to develop long-acting PrRP31 analogues with potent anti-obesity efficacy. A comprehensive series of C18 lipidated PrRP31 analogues was characterized in vitro and analogues with various GPR10 and NPFF2R activity profiles were profiled for bioavailability and metabolic effects following subcutaneous administration in diet-induced obese (DIO) mice. PrRP31 analogues acylated with a C18 lipid chain carrying a terminal acid (C18 diacid) were potent GPR10-selective agonists and weight-neutral in DIO mice. In contrast, acylation with aliphatic C18 lipid chain (C18) resulted in dual GPR10-NPFF2R co-agonists that suppressed food intake and promoted a robust weight loss in DIO mice, which was sustained for at least one week after last dosing. Rapid in vivo degradation of C18 PrRP31 analogues gave rise to circulating lipidated PrRP metabolites maintaining dual GPR10-NPFF2R agonist profile and long-acting anti-obesity efficacy in DIO mice. Combined GPR10 and NPFF2R activation may therefore be a critical mechanism for obtaining robust anti-obesity efficacy of PrRP31 analogues. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF